LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Akciju saraksts・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Atvērts

SektorsVeselības aprūpe

184.26 2.43

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

177.91

Max

187.73

Galvenie mērījumi
By Trading Economics
Ienākumi	262M -15M
Pārdošana	1.6M 996M
EPS	-0.3
Peļņas marža	-1.486
Darbinieki	18,300
EBITDA	-11M 187M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+15.86% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	267M 8.8B
Iepriekšējā atvēršanas cena	181.83
Iepriekšējā slēgšanas cena	184.26

Ziņu noskaņojums

By Acuity

75%

25%

302 / 344 Rangs Healthcare

Charles River Laboratories International Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. jūn. 23:22 UTC

Peļņas

Galvenie tirgus virzītāji

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

2026. g. 3. jūn. 23:09 UTC

Karstas akcijas

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

2026. g. 3. jūn. 20:51 UTC

Peļņas

Costco Reports 15% Sales Growth in May

2026. g. 3. jūn. 20:43 UTC

Peļņas

Broadcom 2Q Revenue Climbs on AI Chip Demand

2026. g. 3. jūn. 23:48 UTC

Tirgus saruna

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

2026. g. 3. jūn. 23:48 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 3. jūn. 23:35 UTC

Tirgus saruna

Oil Futures Fall on Possible Technical Correction -- Market Talk

2026. g. 3. jūn. 23:15 UTC

Tirgus saruna

Peļņas

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

2026. g. 3. jūn. 22:08 UTC

Karstas akcijas

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

2026. g. 3. jūn. 21:54 UTC

Tirgus saruna

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

2026. g. 3. jūn. 21:18 UTC

Peļņas

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

2026. g. 3. jūn. 21:15 UTC

Peļņas

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

2026. g. 3. jūn. 21:13 UTC

Peļņas

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

2026. g. 3. jūn. 21:13 UTC

Peļņas

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

2026. g. 3. jūn. 21:12 UTC

Peļņas

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

2026. g. 3. jūn. 21:09 UTC

Peļņas

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

2026. g. 3. jūn. 21:03 UTC

Peļņas

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

2026. g. 3. jūn. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 3. jūn. 20:43 UTC

Peļņas

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

2026. g. 3. jūn. 20:39 UTC

Iegādes, apvienošanās, pārņemšana

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

2026. g. 3. jūn. 20:37 UTC

Iegādes, apvienošanās, pārņemšana

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

2026. g. 3. jūn. 20:35 UTC

Peļņas

Broadcom Stock Falls Despite Record Results -- Barrons.com

2026. g. 3. jūn. 20:21 UTC

Iegādes, apvienošanās, pārņemšana

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

2026. g. 3. jūn. 20:17 UTC

Peļņas

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

2026. g. 3. jūn. 20:17 UTC

Peļņas

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

2026. g. 3. jūn. 20:15 UTC

Iegādes, apvienošanās, pārņemšana

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

2026. g. 3. jūn. 20:15 UTC

Peļņas

Broadcom 2Q Adj EPS $2.44 >AVGO

2026. g. 3. jūn. 20:15 UTC

Peļņas

Broadcom 2Q EPS $1.91 >AVGO

2026. g. 3. jūn. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 3. jūn. 20:15 UTC

Peļņas

Broadcom 2Q Rev $22.19B >AVGO

Salīdzinājums

Cenas izmaiņa

Charles River Laboratories International Inc Prognoze

Cenas mērķis

By TipRanks

15.86% augšup

Prognoze 12 mēnešiem

Vidējais 208.4 USD 15.86%

Augstākais 235 USD

Zemākais 160 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Charles River Laboratories International Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

11 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 11 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Charles River Laboratories International Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

302 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.